Hepatocellular carcinoma

The high-risk patient

Nicholas N. Nissen, Paul Martin

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the most common hepatic malignancy worldwide. The primary risk factor for the development of HCC is cirrhosis. Even patients without cirrhosis who develop HCC are typically found to have some underlying hepatic abnormality, such as steatohepatitis or chronic viral hepatitis. Although cirrhosis of any cause increases the risk of developing HCC, cirrhosis associated with chronic hepatitis B or C virus infection or hemochromatosis carries the greatest risk. Additional factors such as patient age and sex, duration and severity of liver disease, concurrent alcohol or aflatoxin exposure, liver histology, and alpha-fetoprotein levels also contribute to the relative risk of developing HCC. Vaccination programs aimed at preventing hepatitis B virus infection have been very successful in lowering the incidence of HCC in some areas of the world. Interferon-based therapy, which may control the inflammatory activity in chronic hepatitis C, also holds promise in preventing HCC. Other novel chemopreventative agents, such as glycyrrhizin and polyprenoic acid, may also have a role in preventing HCC, but they require further study before they can be recommended for widespread use.

Original languageEnglish
JournalJournal of Clinical Gastroenterology
Volume35
Issue number5 SUPPL.
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Chronic Hepatitis C
Virus Diseases
Hepatitis B virus
Liver
Glycyrrhizic Acid
Aflatoxins
Hemochromatosis
Chronic Hepatitis B
alpha-Fetoproteins
Fatty Liver
Chronic Hepatitis
Hepacivirus
Interferons
Liver Diseases
Histology
Vaccination
Alcohols
Incidence

Keywords

  • Hepatitis B
  • Hepatitis C
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatocellular carcinoma : The high-risk patient. / Nissen, Nicholas N.; Martin, Paul.

In: Journal of Clinical Gastroenterology, Vol. 35, No. 5 SUPPL., 01.11.2002.

Research output: Contribution to journalArticle

@article{062f04171fb74df0af74b346e7fcef6e,
title = "Hepatocellular carcinoma: The high-risk patient",
abstract = "Hepatocellular carcinoma (HCC) is the most common hepatic malignancy worldwide. The primary risk factor for the development of HCC is cirrhosis. Even patients without cirrhosis who develop HCC are typically found to have some underlying hepatic abnormality, such as steatohepatitis or chronic viral hepatitis. Although cirrhosis of any cause increases the risk of developing HCC, cirrhosis associated with chronic hepatitis B or C virus infection or hemochromatosis carries the greatest risk. Additional factors such as patient age and sex, duration and severity of liver disease, concurrent alcohol or aflatoxin exposure, liver histology, and alpha-fetoprotein levels also contribute to the relative risk of developing HCC. Vaccination programs aimed at preventing hepatitis B virus infection have been very successful in lowering the incidence of HCC in some areas of the world. Interferon-based therapy, which may control the inflammatory activity in chronic hepatitis C, also holds promise in preventing HCC. Other novel chemopreventative agents, such as glycyrrhizin and polyprenoic acid, may also have a role in preventing HCC, but they require further study before they can be recommended for widespread use.",
keywords = "Hepatitis B, Hepatitis C, Hepatocellular carcinoma",
author = "Nissen, {Nicholas N.} and Paul Martin",
year = "2002",
month = "11",
day = "1",
doi = "10.1097/00004836-200211002-00003",
language = "English",
volume = "35",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Hepatocellular carcinoma

T2 - The high-risk patient

AU - Nissen, Nicholas N.

AU - Martin, Paul

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Hepatocellular carcinoma (HCC) is the most common hepatic malignancy worldwide. The primary risk factor for the development of HCC is cirrhosis. Even patients without cirrhosis who develop HCC are typically found to have some underlying hepatic abnormality, such as steatohepatitis or chronic viral hepatitis. Although cirrhosis of any cause increases the risk of developing HCC, cirrhosis associated with chronic hepatitis B or C virus infection or hemochromatosis carries the greatest risk. Additional factors such as patient age and sex, duration and severity of liver disease, concurrent alcohol or aflatoxin exposure, liver histology, and alpha-fetoprotein levels also contribute to the relative risk of developing HCC. Vaccination programs aimed at preventing hepatitis B virus infection have been very successful in lowering the incidence of HCC in some areas of the world. Interferon-based therapy, which may control the inflammatory activity in chronic hepatitis C, also holds promise in preventing HCC. Other novel chemopreventative agents, such as glycyrrhizin and polyprenoic acid, may also have a role in preventing HCC, but they require further study before they can be recommended for widespread use.

AB - Hepatocellular carcinoma (HCC) is the most common hepatic malignancy worldwide. The primary risk factor for the development of HCC is cirrhosis. Even patients without cirrhosis who develop HCC are typically found to have some underlying hepatic abnormality, such as steatohepatitis or chronic viral hepatitis. Although cirrhosis of any cause increases the risk of developing HCC, cirrhosis associated with chronic hepatitis B or C virus infection or hemochromatosis carries the greatest risk. Additional factors such as patient age and sex, duration and severity of liver disease, concurrent alcohol or aflatoxin exposure, liver histology, and alpha-fetoprotein levels also contribute to the relative risk of developing HCC. Vaccination programs aimed at preventing hepatitis B virus infection have been very successful in lowering the incidence of HCC in some areas of the world. Interferon-based therapy, which may control the inflammatory activity in chronic hepatitis C, also holds promise in preventing HCC. Other novel chemopreventative agents, such as glycyrrhizin and polyprenoic acid, may also have a role in preventing HCC, but they require further study before they can be recommended for widespread use.

KW - Hepatitis B

KW - Hepatitis C

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036841865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036841865&partnerID=8YFLogxK

U2 - 10.1097/00004836-200211002-00003

DO - 10.1097/00004836-200211002-00003

M3 - Article

VL - 35

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 5 SUPPL.

ER -